NYSEAMERICAN : TOVX
Theriva Biologics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.1825 USD (Oct 30, 2026, 10:05 AM EDT) · Market cap 8.38M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 8.44M |
| Enterprise Value | 660,251 |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 45.89M |
| Shares Outstanding | 45.89M |
| Shares Change (YoY) | +834.13% |
| Shares Change (QoQ) | +11.74% |
| Owned by Insiders (%) | 1.88% |
| Owned by Institutions (%) | 4.32% |
| Float | 45.03M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 28.15 |
| Forward PS | n/a |
| PB Ratio | 0.69 |
| P/TBV Ratio | 0.69 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 2.20 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.13 |
| Quick Ratio | 1.09 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -101.87% |
| Return on Assets (ROA) | -21.34% |
| Return on Invested Capital (ROIC) | -51.56% |
| Return on Capital Employed (ROCE) | -53.05% |
| Weighted Average Cost of Capital (WACC) | 7.61% |
| Revenue Per Employee | $18,750 |
| Profits Per Employee | -$820,500 |
| Employee Count | 16 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.19 |
| 52-Week Price Change | -41.10% |
| 50-Day Moving Average | 0.22 |
| 200-Day Moving Average | 0.24 |
| Relative Strength Index (RSI) | 37.21 |
| Average Volume (20 Days) | 4,934,478 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.85M |
| Short Previous Month | 1.59M |
| Short % of Shares Out | 4.02% |
| Short % of Float | 4.10% |
| Short Ratio (days to cover) | 3.68 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 300,000 |
| Gross Profit | 300,000 |
| Operating Income | -12.07M |
| Pretax Income | -11.62M |
| Net Income | -13.13M |
| EBITDA | -11.96M |
| EBIT | -12.07M |
| Loss Per Share | -$0.42 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 11.34M |
| Total Debt | 3.55M |
| Net Cash | 7.78M |
| Net Cash Per Share | $0.17 |
| Equity (Book Value) | 12.19M |
| Book Value Per Share | 0.27 |
| Working Capital | 1.56M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -12.74M |
| Capital Expenditures | -22,000 |
| Depreciation & Amortization | 103,000 |
| Net Borrowing | -14,000 |
| Free Cash Flow | -12.76M |
| FCF Per Share | -$0.28 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -4,022.00% |
| Pretax Margin | -3,872.67% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -834.13% |
| Shareholder Yield | -834.13% |
| Earnings Yield | -226.51% |
| FCF Yield | -151.16% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 26, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -15.49 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |